Cephalon, Inc.

Brickell Biotech, Inc.

Bristol-Myers Squibb Compnay

Amira Pharmaceuticals, Inc.

Panmira Pharmaceuticals, LLC

Jason Edward Brittain

Joe Craig Franklin

Christopher David King

Brian Andrew Stearns

Kevin Ross Holme

Thomas Jon Seiders

Victor W Rosso

Described herein is the DPantagonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DPantagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DPantagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D-dependent or prostaglandin D-mediated diseases or conditions.

DP2 antagonist and uses thereof

Described herein is the DPantagonist [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4&#x2032;-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DPantagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D-dependent or prostaglandin D-mediated diseases or conditions.

Described herein is the LPA1 antagonist 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.

Polycyclic LPA1 antagonist and uses thereof

The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

Growing community of inventors

El Cajon, CA, United States of America

Jason Edward Brittain